Since then, evidence of melanoma dependency on MAPK pathway accumulated and its inhibition by either BRAF or MEK inhibitors (BRAFi and MEKi, respectively) emerged as a therapeutic strategy [2]. Here, MAP2K7 is linked to melanoma.